Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M42.1Revenue (TTM) $M13.9Net Margin (%)-87.1Altman Z-Score-10.1
Enterprise Value $M34.2EPS (TTM) $-0.8Operating Margin %-73.0Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-87.1Higher ROA y-yN
Price/Book9.610-y EBITDA Growth Rate %--Quick Ratio2.5Cash flow > EarningsY
Price/Sales2.05-y EBITDA Growth Rate %-15.2Current Ratio2.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-109.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-718.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.3ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NBY

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

NBY is held by these investors:

NBY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Najafi RaminCEO, 10% Owner 2015-08-20Buy480$11.75-76.6view
Pioneer Pharma (Singapore) Pte10% Owner 2015-03-03Buy103,600$15-81.67view
SIECZKAREK MARK MDirector 2015-03-03Buy6,667$15-81.67view
Najafi RaminChairman 2015-03-03Buy6,667$15-81.67view
Najafi RaminChairman 2014-12-12Buy2,000$16.25-83.08view
PAULSON THOMAS JCFO 2014-12-12Buy400$17-83.82view
Stroman David W.SVP, Ophthalmic Product Devt. 2014-12-12Buy400$16.5-83.33view
Najafi RaminChairman 2014-12-11Buy800$15-81.67view
PAULSON THOMAS JCFO 2014-12-09Buy400$16.75-83.58view
Najafi RaminChairman 2014-12-05Buy1,000$16.25-83.08view

Press Releases about NBY :

Quarterly/Annual Reports about NBY:

News about NBY:

Articles On GuruFocus.com
Novabay Pharmaceuticals' CEO Dr. Ramin Najafi Interviewed by The Life Sciences Report Jun 25 2015 
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

More From Other Websites
NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE MKT May 19 2017
NovaBay Pharmaceuticals Reports First Quarter 2017 Financial Results May 11 2017
NovaBay Pharmaceuticals to Hold 2017 First Quarter Conference Call on May 11, 2017 May 04 2017
Avenova from NovaBay Pharmaceuticals is Effective for Managing Dry Eye before Refractive and... May 02 2017
NovaBay's intelli-Case Can Safely and Effectively Disinfect Contact Lenses, CEOCFO Magazine Reports Apr 17 2017
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017 Mar 28 2017
Avenova from NovaBay Pharmaceuticals Effective for Painful Eye Condition Mar 28 2017
Edited Transcript of NBY earnings conference call or presentation 23-Mar-17 8:30pm GMT Mar 24 2017
NovaBay Pharmaceuticals Reports 2016 Full Year and Fourth Quarter Financial Results and Provides... Mar 23 2017
NovaBay Pharmaceuticals to Hold 2016 Fourth Quarter and Full Year Conference Call on March 23, 2017 Mar 16 2017
NovaBay Pharmaceuticals to Present Features and Benefits of the intelli-Case at FDA Public Advisory... Mar 09 2017
Explaining Innovative Drug Technologies Through Animation Mar 08 2017
NovaBay Pharmaceuticals to Present at 29th Annual ROTH Conference Mar 07 2017
Relief from Painful Dry Eye Can be a Real Valentine's Day Gift Feb 14 2017
NovaBay CEO Sees Continued Double-Digit Revenue Growth in 2017 Jan 30 2017
NovaBay Pharmaceuticals' "Avenova" Helping Patients with Contact Lens Intolerance Jan 27 2017
NovaBay Pharmaceuticals Announces Preliminary Sales for the Fourth Quarter of 2016 Jan 09 2017
NovaBay's Avenova Brings Quick Relief to Children Suffering from Eye Conditions, Writes Steven J.... Dec 19 2016
Five Stocks Under $5.00 for December (NAK, GGB) Nov 23 2016
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14,... Nov 14 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)